Head-to-head evidence
Idecabtagene vicleucel vs IM21 CAR-T cells
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA · full Multiple Myeloma pipeline
Idecabtagene vicleucel
Marketed by Bristol-Myers Squibb
NCT03651128 · Phase 3 · completed
Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).
Next expected readout: May 2027 · NCT05393804 (registry estimate)
IM21 CAR-T cells
Developed by Beijing Immunochina Medical Science & Technology Co., Ltd.
NCT03711864 · Phase 1 · status unknown
This is a small, unblinded, single-arm safety study with no comparison group, and no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Idecabtagene vicleucel's landscape · IM21 CAR-T cells's landscape